TruScreen Ltd – Resignation of Director

NZX and Media Release 20 December 2017
NZX Limited
WELLINGTON
Resignation of Director

TruScreen Limited (NZAX: TRU)

Cervical cancer technology company, TruScreen Limited (NZAX:TRU) announces that Mr
Sean Joyce has resigned as a director.
TruScreen Chairman, Mr Robert Hunter said “We wish to thank Mr Joyce for his service to
the company as he has made a meaningful contribution since its inception. This vacancy
creates an opportunity for the company to continue its process of renewal and refreshment
and ensure that any new appointment has the appropriate skills and capabilities to assist
the company at this stage of its development.”
It is noted that under the NZAX listing rule 3.2.1, the company now has one director
ordinarily resident in New Zealand and the board will seek to fill the casual vacancy with
another New Zealand resident director as soon as practicably possible.

Martin Dillon
CEO

For more information visit www.truscreen.com


Contact
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com

-ENDS-

About TruScreen:
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial
neoplasia (CIN). A Single Use Sensor (SUS) is used
for each patient to protect against cross-infection.